Policy Intel & Events

Policy Intel & Events

The Latest from Roberti Global

Roberti Global insights on policy trends, political analysis, firm updates, and front-line perspectives from Washington.

Eisai-Developed Treatment for Alzheimer’s Disease Approved by FDA

Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM) for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Eisai, containing 360 mg/1.8 mL (200 mg/mL)